Company Description

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.

It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

Country	Netherlands
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	77
CEO	Michael Davidson

Contact Details

Address: Gooimeer 2-35 Naarden, 1411 DC Netherlands
Phone	31 35 206 2971
Website	newamsterdampharma.com

Stock Details

Ticker Symbol	NAMS
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1936258
ISIN Number	NL00150012L7
SIC Code	2834

Key Executives

Name	Position
Dr. Michael Harvey Davidson FACC, Facp., M.D.	Chief Executive Officer, President and Executive Board Member
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.	Founder, Chief Scientific Officer, Member of Executive Board and Director
Mayur Amrat Somaiya	Chief Financial Officer
Douglas F. Kling	Chief Operating Officer
Juliette Audet M.B.A., M.Sc.	Chief Strategy and Business Officer
Louise Kooij	Chief Accounting Officer
Matthew Philippe	Executive Vice President &Head of Investor Relations
Bob Rambo	Executive Vice President of Marketing
Maryellen McQuade	Chief People Officer
Dr. Marc Ditmarsch M.D.	Chief Development Officer

Latest SEC Filings

Date	Type	Title
Jan 20, 2026	144	Filing
Jan 9, 2026	8-K	Current Report
Jan 7, 2026	144	Filing
Jan 6, 2026	144	Filing
Jan 5, 2026	144	Filing
Jan 5, 2026	144	Filing
Jan 5, 2026	144	Filing
Dec 23, 2025	144	Filing
Dec 4, 2025	SCHEDULE 13D/A	Filing
Dec 2, 2025	144	Filing

View All SEC Filings